This session reviews the impact of recent evidence on complex PCI, highlighting the value of intracoronary imaging (CHIP IVUS trial) and left ventricular assist devices (CHIP BCIS 3 trial). Through case discussions, participants reflect on how these innovations influence daily clinical practice and enhance procedural planning...

Examine contemporary strategies for distal left main bifurcation disease treatment, including debates on complex bifurcation and high-risk PCI approaches. The session emphasizes the critical role of coronary imaging in guiding decision-making and showcases clinical cases illustrating management of left main interventions under challenging conditions.

Explore a series of challenging cases in coronary bifurcation interventions, highlighting complex decision-making scenarios, pharmaco-invasive strategies guided by IVUS, and tailored techniques for reintervention. Emphasis is placed on imaging-guided PCI and simplifying complex double bifurcation and long lesion treatments to optimize patient outcomes.

This session focuses on the innovative use of drug-coated balloons (DCB) in chronic total occlusion (CTO) interventions. It reviews combined plaque modification techniques, complex multivessel PCI cases involving CTOs, and strategy considerations such as hybrid therapy versus full metal jacket, emphasizing vessel biology preservation during revascularisation.

Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.